Financial Archives - Page 4 of 6 -

Pfizer expects revenues from its BioNTech-partnered COVID-19 vaccine to reach an eye-watering $26 billion this year, catapulting it

Pfizer says COVID-19 jab could rake in $26bn this year

https://pharmaphorum.com/news/pfizer-says-covid-19-jab-could-rake-in-26bn-this-year/

News/ News/ Patients

23andMe goes public using Richard Branson’s blank cheque company

Phil Taylor 23andMe, Financial, genetic testing, M&A, Virgin Group 0 Comment

DNA testing company 23andMe has signed a deal to merge with a ‘blank cheque’ company set up by

23andMe goes public using Richard Branson’s blank cheque company

https://pharmaphorum.com/news/23andme-goes-public-using-richard-bransons-blank-cheque-company/

News/ News/ Sales and Marketing

AZ closes $400 million Atacand sale to Germany’s Cheplapharm

Phil Taylor AstraZeneca, Atacand, cardiovascular, Cheplapharm, Financial 0 Comment

AstraZeneca has completed the sell-off of another mature product, hiving off its Atacand cardiovascular franchise to Cheplapharm as

AZ closes $400 million Atacand sale to Germany’s Cheplapharm

https://pharmaphorum.com/news/az-closes-400-million-atacand-sale-to-germanys-cheplapharm/

News/ News/ R&D

BMS/Celgene merger payout evaporates as CVR deadline passes

Phil Taylor Bristol-Myers Squibb, Celgene, Financial, M&A 0 Comment

Former Celgene shareholders holding on for a windfall payment from Bristol-Myers Squibb tied to FDA approval of three

BMS/Celgene merger payout evaporates as CVR deadline passes

https://pharmaphorum.com/news/bms-celgene-merger-payout-evaporates-as-cvr-deadline-passes/

News/ News/ Sales and Marketing

Gilead Q3 revenue rise bolstered by $873m Veklury sales

Phil Taylor coronavirus, COVID-19, Financial, Gilead Sciences, remdesivir, Veklury 0 Comment

Gilead Sciences is the first and so far only company to claim FDA approval for a COVID-19 treatment

Gilead Q3 revenue rise bolstered by $873m Veklury sales

https://pharmaphorum.com/news/gilead-q3-revenue-rise-bolstered-by-873m-veklury-sales/

News/ News/ Sales and Marketing

Novartis CEO thinks 2nd health lockdown unlikely, as Q3 sales stabilise

Phil Taylor coronavirus, Cosentyx, COVID-19, Entresto, Financial, Kisqali, Novartis, Zolgensma 0 Comment

Novartis’ pharmaceutical sales recovered in the third quarter of this year after an earlier COVID-19 decline, as new

Novartis CEO thinks 2nd health lockdown unlikely, as Q3 sales stabilise

https://pharmaphorum.com/news/novartis-ceo-thinks-2nd-health-lockdown-unlikely-as-q3-sales-stabilise/

The unprecedented challenge of pricing a coronavirus vaccine

News/ News/ R&D

CureVac claims €75m in EU funding for mRNA COVID-19 vaccine

Phil Taylor coronavirus, coronavirus vaccine, COVID-19, CureVac, EU, Financial 0 Comment

German vaccine firm CureVac has been awarded a €75 million loan from the European Investment Bank to boost

CureVac claims €75m in EU funding for mRNA COVID-19 vaccine

https://pharmaphorum.com/news/curevac-claims-e75m-in-eu-funding-for-mrna-covid-19-vaccine/

News/ News/ News/ News/ Oncology/ R&D/ Sales and Marketing

Royalty Pharma shares surge 59% after $2.2 billion IPO

Phil Taylor Financial, IPO, royalty pharma 0 Comment

Biopharma initial public offerings are back with a bang after a coronavirus pandemic lull, as Royalty Pharma raised

Royalty Pharma shares surge 59% after $2.2 billion IPO

https://pharmaphorum.com/news/royalty-pharma-shares-surge-59-after-2-2-billion-ipo/

Market Access/ News/ News/ News/ Oncology

Celgene investors’ CVR payment looks rocky, as FDA rejects ide-cel file

Phil Taylor Bristol-Myers Squibb, Celgene, Financial, investors, Mergers and acquisitions 0 Comment

The chances of former shareholders in Celgene missing out on the big pay-out from their contingent value right

Celgene investors’ CVR payment looks rocky, as FDA rejects ide-cel file

https://pharmaphorum.com/news/celgene-investors-merger-payment-looks-rocky-as-fda-rejects-ide-cel-file/

Trending

Financial

Login